MedTrace Logo

ITV Extension Study

NCT00332930 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2007-02-27

No results posted yet for this study

Summary

The objective of this phase I/II therapeutic human immunodeficiency virus (HIV) vaccine candidate study is to provide proof of concept for a HIV antigen delivery system in terms of safety, virological effects and selected immune responses in HIV infected individuals after cessation of antiretroviral combination therapy (ART).

Conditions

Interventions

BIOLOGICAL

recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens

BIOLOGICAL

HIV gag-pol antigens and interferon-gamma (IFN-y)

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • Virax Pty. Ltd,

    collaborator INDUSTRY

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • David A Cooper, AO DSc MD FRACP FRCPA FRCP · National Centre in HIV Epidemiology and Clinical Research.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Completion
2003-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00332930 on ClinicalTrials.gov